Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mFOLFIRINOX and SBRT in Non-metastatic Unresectable Pancreatic Adenocarcinoma
NCT03991962Phase 2Active, not recruiting
- Sponsor
- Yale University
- Start
- Sep 2019
- Primary completion
- Aug 2026
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of mFOLFIRINOX in pancreatic adenocarcinoma (PDAC), sponsored by Yale University. Primary endpoint: Progression Free Survival at 9 months. Started Sep 2019; status: active, not recruiting.
02
Drugs
mFOLFIRINOX
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT03991962.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03991962.